Release
Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention
The Brief
- The FDA approved asundexian (brand name Sunharbo) for secondary stroke prevention.
- Asundexian is described as the first factor XIa (FXIa) inhibitor approved for this use.
- It is an oral, direct, small-molecule FXIa inhibitor.
Why it matters
It adds a new oral anticoagulant class for preventing recurrent stroke, which science and medical readers may track as an alternative to existing antithrombotic drugs.
Who’s affected
- physicians treating stroke patients
- patients with a history of stroke
- pharmaceutical and drug development researchers
- #stroke prevention
- #anticoagulants
- #factor xi inhibitor
- #fda approval
- #asundexian
(MedPage Today) -- The FDA approved asundexian (Sunharbo) as the first factor XIa (FXIa) inhibitor for secondary stroke prevention, the agency announced on Monday. Asundexian, an oral, direct, small-molecule inhibitor of FXIa, is indicated for...
Timeline
FDA announced approval of asundexian (Sunharbo) for secondary stroke prevention
MedPageToday.com - medical news for physicians
Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention